AnaptysBio's skin disease drug meets main goal in late-stage study
09/10/2023 13:05
Oct 9 (Reuters) - AnaptysBio Inc ANAB.O said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila) ((Khushi.Mandowara@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties